Literature DB >> 15004435

Inward remodeling of the rabbit aorta is blocked by the matrix metalloproteinase inhibitor doxycycline.

David W Courtman1, Christopher D Franco, Qinghe Meng, Michelle P Bendeck.   

Abstract

Constrictive arterial remodeling accounts for a significant proportion of lumen loss in atherosclerotic progression and postangioplasty stenosis. Recent research suggests that constrictive remodeling is mediated by turnover of the extracellular matrix. We hypothesized that remodeling could be attenuated by treatment with the safe, effective matrix metalloproteinase (MMP) inhibitor doxycycline. Female rabbit abdominal aortas were denuded using a 4-Fr balloon embolectomy catheter, and reinjured 3 weeks later. Treatment with 30 mg/kg/day doxycycline was begun the day before the second injury. At 6 weeks after injury, lumen area measured 13.1 +/- 1.2 mm(2) in controls compared to 17.5 +/- 1.6 mm(2) in doxycycline-treated rabbits (p = 0.05). At 4 days after injury, MMP-2 activity was increased compared to uninjured controls, but doxycycline treatment reduced MMP-2 activity. Doxycycline treatment also inhibited fibrillar collagen deposition in the intima by 87% as detected by polarized light microscopy. Doxycycline was an effective inhibitor of constrictive arterial remodeling in the rabbit aorta. Treatment reduced MMP activity and attenuated the deposition of extracellular matrix particularly in the intima. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004435     DOI: 10.1159/000077145

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  7 in total

1.  Matrix metalloproteinases and small artery remodeling.

Authors:  Luis A Martinez-Lemus; Edgar Luis Galiñanes
Journal:  Drug Discov Today Dis Models       Date:  2011

2.  MMP-9 regulates both positively and negatively collagen gel contraction: a nonproteolytic function of MMP-9.

Authors:  Olivier D Defawe; Richard D Kenagy; Chun Choi; Samuel Y C Wan; Christophe Deroanne; Betty Nusgens; Natzi Sakalihasan; Alain Colige; Alexander W Clowes
Journal:  Cardiovasc Res       Date:  2004-12-15       Impact factor: 10.787

3.  Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices.

Authors:  Christopher Franco; Bernard Ho; Diane Mulholland; Guangpei Hou; Muzharul Islam; Katey Donaldson; Michelle Patricia Bendeck
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

4.  Protein kinase A-regulated assembly of a MEF2{middle dot}HDAC4 repressor complex controls c-Jun expression in vascular smooth muscle cells.

Authors:  Joseph W Gordon; Christina Pagiatakis; Jahan Salma; Min Du; John J Andreucci; Jianzhong Zhao; Guangpei Hou; Robert L Perry; Qinghong Dan; David Courtman; Michelle P Bendeck; John C McDermott
Journal:  J Biol Chem       Date:  2009-04-23       Impact factor: 5.157

5.  Natural history of experimental arterial chronic total occlusions.

Authors:  Ronen Jaffe; General Leung; Nigel R Munce; Amandeep S Thind; Howard Leong-Poi; Kevan J T Anderson; Xiuling Qi; Judy Trogadis; Ariella Nadler; Davida Shiff; Jamie Saperia; Julia Lockwood; Chaim Jacobs; Beiping Qiang; Aaron Teitelbaum; Alexander J Dick; John D Sparkes; Jagdish Butany; Graham A Wright; Bradley H Strauss
Journal:  J Am Coll Cardiol       Date:  2009-03-31       Impact factor: 24.094

6.  The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats.

Authors:  Jianxin Lu; Jingzhang Ji; Howard Meng; David Wang; Bo Jiang; Lixin Liu; Edward Randell; Khosrow Adeli; Qing H Meng
Journal:  Cardiovasc Diabetol       Date:  2013-04-05       Impact factor: 9.951

7.  Resveratrol inhibits matrix metalloproteinases to attenuate neuronal damage in cerebral ischemia: a molecular docking study exploring possible neuroprotection.

Authors:  Anand Kumar Pandey; Pallab Bhattacharya; Swet Chand Shukla; Sudip Paul; Ranjana Patnaik
Journal:  Neural Regen Res       Date:  2015-04       Impact factor: 6.058

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.